Skip to main content

Market Overview

US Stock Futures Signal Higher Start On Wall Street

Share:
US Stock Futures Signal Higher Start On Wall Street

Pre-open movers

US stock futures traded higher in early pre-market trade. Data on weekly jobless claims will be released at 8:30 a.m. ET, while the Markit PMI services index for December will be released at 9:45 a.m. ET. The general conditions index of the Philadelphia Fed's Survey for December and the Conference Board's index of leading indicators for November will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average jumped 181 points to 17,473.00, while the Standard & Poor's 500 index futures rose 22.20 points to 2,030.40. Futures for the Nasdaq 100 index climbed 53.25 points to 4,212.75.

A Peek Into Global Markets

European markets were higher today, with the Spanish Ibex Index gaining 2.69%, STOXX Europe 600 Index rising 2.07%. German DAX 30 index climbed 2.08%, French CAC 40 Index gained 2.57% and London's FTSE 100 Index rose 0.98%.

In Asian markets, Japan's Nikkei Stock Average rose 2.32%, Hong Kong's Hang Seng Index climbed 1.09%, China's Shanghai Composite Index fell 0.11% and India's Sensex jumped 1.56%.

Broker Recommendation
Analysts at Longbow Research upgraded Joy Global, Inc. (NYSE: JOY) from Underperform to Neutral. The price target for Joy Global is set to $50.

Joy Global's shares closed at $46.14 yesterday.

Breaking news

  • Winnebago Industries, Inc. (NYSE: WGO) reported weaker-than-expected fiscal first-quarter earnings. To read the full news, click here.
  • Akers Biosciences, Inc. (NASDAQ: AKER) has entered into its first European distribution agreements since the installment of its international vice president in August 2014. To read the full news, click here.
  • TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG) today announced the initiation of a randomized Phase 2 clinical trial of SHAPE in subjects with early stage cutaneous T cell lymphoma ("CTCL"). To read the full news, click here.
  • BioCryst Pharmaceuticals, Inc., (NASDAQ: BCRX) today announced that it has dosed the first patient in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered BCX4161 in patients with hereditary angioedema (HAE). To read the full news, click here.
 

Related Articles (WGO + JOY)

View Comments and Join the Discussion!

Posted-In: Longbow Research US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com